234 CHURCH STREET, NEW HAVEN, CT
News
Earnings Release
Sells Interest in REV102 Program to Recursion Pharmaceuticals
News, Material Contracts
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Updates
Discontinue Development of RLYB212 for Prevention of FNAIT
News, Underwriting Agreement
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
SEC Staff Correspondence
S-1MEF